Meridian Medical Technologies
This article was originally published in The Gray Sheet
Executive Summary
Firm recalls 47 lots of EpiPen and EpiPen Jr. auto-injectors because some of the devices "may not provide effective doses of medication to treat acute allergic emergencies (anaphylaxis)," the firm reports May 8. The Class I recall seeks to retrieve auto-injectors distributed in the U.S., Germany, Israel, Denmark, Canada, Turkey, Australia, Greece and South Africa. No patients have been affected by the problem, which "arose in the process of advancing our automated production capabilities," Meridian states